<DOC>
	<DOCNO>NCT00495287</DOCNO>
	<brief_summary>The study set ass : 1 . Standard-dose versus high-dose remission induction therapy . A standard ICE chemotherapy v sequential high-dose cytarabine , appropriate supportive/prophylactic measure , follow morphological , cytogenetic molecular monitoring remission . 2 . A risk-oriented postremission therapy : HR patient electively submit allogeneic stem cell transplantation ( allo-SCT ) , whenever possible ( related/unrelated donor/cord blood ; ablative/non-ablative conditioning accord national local protocol guideline ) . Provided sufficient blood stem cell previously collect ( &gt; 2x10e6/kg Cluster Differentiation 34 cell ) , SR patient HR patient exclude allo-SCT age 65 year less randomize : myeloablative autologous blood stem cell transplantation v non-myeloablative , multicycle , autologous blood stem cell-supported high-dose cytarabine-based therapy . - HR/SR patient unable randomized inadequate blood stem cell yield receive intermediate-dose consolidation ; patient age &gt; 65 year treat age-adapted therapy .</brief_summary>
	<brief_title>A Remission Induction Therapy Risk-oriented Postremission Strategy Adult Acute Myelogenous Leukemia ( AML )</brief_title>
	<detailed_description>Adult AML difficult-to-treat illness biological therapeutic reason . Most patient age &gt; 50 year and/or present comorbid condition and/or display high-risk AML-related feature ( poor risk , cytogenetics , prior myelodysplasia , secondary AML ) . This result unsatisfactory response conventional first-line therapy make difficult apply effective post-remission consolidation option ( allo-SCT younger patient HR feature , autologous blood stem cell transplantation high-dose cytarabine-based therapy remainder ) . In prior , phase II uncontrolled NILG trial ( registered NCT 00400637 ) , two-step increase intensity induction adopt order optimize induction result . 51 % ICE-refractory case respond salvage regimen , irrespective risk class . In study , HR patient send allografting whereas SR patient ( clinico-cytogenetics criterion ) receive three high-dose cytarabine-based cycle , one support fixed amount autologous blood-stem cell ( 1-2x10e6/kg Cluster Differentiation 34 cell cell ) , minimize risk high-dose cytarabine-related myelosuppression increase treatment intensity reduce intercycle delay . DFS 41 % 5 year , 58 % SR patient age &lt; 55 year , 47 % SR patient age &gt; 55 year , 47 % HR patient identifiable donor . No treatment-related death occur pancytopenic phase 118 patient receive 299 blood stem-cell support high-dose cytarabine cycle . These fact lead present trial , 1 ) high-dose induction formerly use salvage directly compare standard ICE chemotherapy 2 ) blood-stem cell support multicycle high-dose cytarabine program directly compare standard autologous blood stem cell transplantation . RANDOM 1 CYCLE 1 - Standard ICE ( drug IV route ) : idarubicin 12 mg/m2/d dd 1-3 , cytarabine 100 mg/m2/bd dd 1-7 , etoposide 100 mg/m2/d dd 1-5 , G-CSF 11 . - High-dose sequential ( drug IV route ) : cytarabine 2* g/m2/bd dd 1-2 8-9 , idarubicin 18 mg/m2/d dd 3 10 , G-Colony Stimulating Factory ( G-CSF ) 11 . *1 g/m2 frail patient age 60-65 age &gt; 65 year . CYCLE 2 ( CR achieve cycle 1 ) : Standard IC : idarubicin 10 mg/m2/d dd 1-3 , cytarabine 100 mg/m2/bd dd 1-7 , G-CSF . CYCLE 3 : Intermediate-dose cytarabine 1 g/m2/bd dd 1-4 follow G-CSF stem cell collection ( 1-2x10e6/kg CD34+ cell three separate bag ) ALLO-SCT ( Allogeneic Stem Cells Transplantation ) : All HR patient eligible allo-SCT first therapeutic option . Allo-SCT procedure : type accord local protocols/guidelines . RANDOM 2 All SR patient HR one exclude allo-SCT : - Autologous blood stem cell transplantation BU-CY2 regimen ( Busulfan 0.8 mg/kg IV dd -8 -5 , Cy 60 mg/kg/d dd -4 -3 , autograft 0 ( 2-6x10e6/kg CD34+ cell ) G-CSF +1 . - Autologous blood stem cell support multicycle therapy ( x3 , monthly ) cytarabine 2 g/m2/bd dd 1-5 , idarubicin 8 mg/m2/d dd 1-2 , autograft 6 ( 1-2x10e6/kg CD34+ cell ) G-CSF 8 . Patients exclude Random 2 well allo-SCT receive attenuate , unsupported consolidation 1-2 intermediate-dose cytarabine cycle . Patients age &gt; 65 year exclude Random 2 . RISK CLASSIFICATION Cytogenetic risk classification base MRC/ECOG-SWOG/CALGB criterion ( cytogenetic risk class : favorable , normal/intermediate , unfavorable , , unknown ) ; clinical risk classification base select diagnostic criterion response chemotherapy cycle 1 . The final risk model integrate cytogenetic clinical risk encompass two broad risk class ( SR HR ) . - Standard risk ( SR ) : favorable cytogenetics , CR achieve cycle 1 ; normal/intermediate cytogenetics , CR achieve cycle 1 , lack high-risk characteristic . - High risk ( HR ) : unfavorable cytogenetics ; normal/intermediate cytogenetics high-risk characteristic ( WBC &gt; 50x10e9/l , FAB M0,6,7 corresponding WHO , secondary AML , Myelodysplastic Syndrome ( MDS ) -associated AML , hepatosplenomegaly , FLT3 mutation , CR ) achieve cycle , persistent cytogenetic abnormality CR ) , other/unknown cytogenetics .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<criteria>Inclusion criterion ( Random 1 ) : Age 16+ year Diagnosis untreated ( hydroxyurea/cyclophosphamide ) acute myelogenous leukemia ( AML , include myeloid sarcoma ) highrisk myelodysplasia ( RAEB2 ) , either de novo follow antecedent hematological disorder , secondary chemoradiotherapy cancer Signed informed consent Adequate sampling full cytological , cytochemical , cytogenetic immunobiological disease characterization revise FAB , EGIL WHO criteria ECOG performance status 02 reversible ECOG 3 score follow intensive care complication . Exclusion criterion : Diagnosis acute promyelocytic leukemia Preexisting , uncontrolled pathology cardiac disease ( congestive/ischemic , acute myocardial infarction within past 3 month , untreatable arrythmias , NYHA class III IV ) , severe liver disease serum bilirubin &gt; 3 mg/dL and/or ALT &gt; 3 x upper normal limit ( unless attributable AML ) , kidney function impairment serum creatinine &gt; 2 mg/dL ( unless attributable AML ) , severe neuropsychiatric disorder impair patient 's ability understand sign inform consent , cope intend treatment plan Known HIV positive serology Other active hematological nonhematological cancer life expectancy &lt; 1 year Pregnancy ( fertile woman advise become pregnant treatment ; male patient adopt contraceptive method )</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Acute myelogenous leukemia</keyword>
	<keyword>Adult patient</keyword>
	<keyword>Cytogenetic risk class</keyword>
	<keyword>Clinico-cytogenetic risk model</keyword>
	<keyword>Risk-oriented therapy</keyword>
</DOC>